We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.75% | 25.45 | 25.54 | 25.20 | 25.33 | 46,479,621 | 00:58:17 |
From Apr 2019 to Apr 2024
By Chris Wack
Pfizer Inc. (PFE) said Monday that the U.S. Food and Drug Administration has approved both Vyndaqel, or tafamidis meglumine, and Vyndamax (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
The health-care company said in a release that Vyndaqel and Vyndamax are two oral formulations of the first-in-class transthyretin stabilizer tafamidis, and the first and only medicines approved by the FDA to treat hereditary transthyretin-mediated amyloidosis.
Pfizer said that about 100,000 people in the U.S. have hereditary transthyretin-mediated amyloidosis.
The company said that approved recommended dosage is either Vyndaqel 80 mg orally once-daily, taken as four 20 mg capsules, or Vyndamax 61 mg orally once-daily, taken as a single capsule.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 06, 2019 07:23 ET (11:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
